Lab21 to Offer Saladax Chemotherapy Management Tests | GenomeWeb

NEW YORK (GenomeWeb News) – Saladax Biomedical today said that Lab21 will offer the firm's Personalized Chemotherapy Management assays as a service offering in the UK, Ireland, and Middle East, under a distribution agreement between the firms.

Bethlehem, Pa.-based Saladax said that Lab21 is the first clinical reference lab to offer testing services based on the firm's 5-fluorouracil PCM reagent kits. Cambridge, UK-based Lab21 will market the dose-management service under the trade name DoseCheck.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.